Aclidinium Bromide
PreclinicalSmall molecule
AstraZenecaAclidinium Bromide is a small molecule that works as a Muscarinic Acetylcholine Receptor M3 Antagonist.[2] It is being investigated across 5 indications, with its most advanced program in Preclinical.[1]
Aclidinium Bromide is one of 79 small molecule programs targeting Bronchitis. It is currently in Preclinical.
5
Indications
34
Total Trials
0
Active Trials
78
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
175 competitors in Asthma
#DrugCompanyPhaseTrials
1Celexa
AbbViePreclinical
Aclidinium Bromide
AstraZenecaPreclinical
Arcoxia
NovartisPreclinical
Solu-Medrol
MMassachusetts Eye and Ear Infirmary
Preclinical
DUPIXENT
RegeneronPreclinical
Paracetamol
GSKPreclinical
Blood Withdrawn
Emergent BioSolutionsPreclinical
Blood Collection
AAssistance Publique - Hôpitaux de Paris
Preclinical
Lexapro
SShirley Ryan AbilityLab
Preclinical
Biological Drug
UUniversitaire Ziekenhuizen KU Leuven
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Chronic Obstructive Pulmonary Disease21 trials
Show 18 more trials
Efficacy and Safety4 trials
Cardiovascular2 trials
Monotherapy1 trial
5 more indications
Tics1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Aclidinium Bromide. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Muscarinic Acetylcholine Receptor M3 Antagonist[2]
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company